Gilead Sciences shares gain after topping expectations despite lower remdesivir sales By Investing.com
[ad_1] © Reuters Gilead Sciences shares gain after topping expectations despite lower remdesivir sales By Sam Boughedda Gilead Sciences (NASDAQ:) shares rallied in early Friday trading in reaction to the company’s latest earnings report, which saw it beat top and bottom-line consensus expectations. The biopharmaceutical company posted fourth-quarter of $1.67 per share, $0.17 above the … Read more